Trial Profile
A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs HSP Gp96 vaccine Cure and Sure Biotech (Primary) ; Temozolomide (Primary) ; Cyclophosphamide
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- Sponsors Cure&Sure Biotech
- 10 Mar 2020 Planned End Date changed from 20 Aug 2023 to 20 Aug 2024.
- 10 Mar 2020 Status changed from not yet recruiting to recruiting.
- 05 Sep 2018 New trial record